Iomab-B is a new type of treatment for patients with relapsed or refractory acute myeloid leukemia (r/r AML), a type of blood cancer that is difficult to treat and has a poor prognosis.
Iomab-B is a targeted radiotherapy that uses a monoclonal antibody to deliver radiation directly to the bone marrow and spleen, where most of the leukemia cells are located.
This way, Iomab-B can destroy the cancer cells and prepare the patient for a bone marrow transplant (BMT), which is a potentially curative procedure.
Iomab-B has been tested in a large clinical trial called SIERRA, which showed positive results for patients who received Iomab-B and BMT compared to those who received conventional chemotherapy and BMT.
Some of the key findings from the SIERRA trial are:
• All patients who received Iomab-B were able to access BMT, while only 17% of patients who received chemotherapy were able to do so1.
• Patients who received Iomab-B had a higher rate of remission after BMT than those who received chemotherapy (75% vs 6.3%)1.
• Patients who received Iomab-B had a longer median overall survival than those who received chemotherapy (6.37 months vs 1.66 months)2.
• Patients who had a TP53 gene mutation, which is associated with worse outcomes in AML, had a similar median overall survival as those who did not have the mutation when they received Iomab-B (5.72 months vs 6.37 months)2.
• Iomab-B was well tolerated and had manageable side effects1.
Iomab-B is a promising new therapy for r/r AML patients who need a BMT but cannot achieve remission with conventional chemotherapy.
It is currently under review by the FDA for approval3.
If you want to learn more about Iomab-B, you can visit the official website of the SIERRA trial4 or the website of Actinium Pharmaceuticals, the company that developed Iomab-B1.
